Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma.

Keyvan Nouri, Christopher O'Connell, Maria Patricia Rivas

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Topical imiquimod is an immune response modifier FDA approved for the treatment of anogenital warts. Recent studies have reported its effectiveness in the treatment of some types of basal cell carcinomas. There have also been some case reports and case series reporting success treating of squamous cell carcinoma in situ with imiquimod. We report two patients with squamous cell carcinoma in situ and one with invasive squamous cell carcinoma treated with 5% imiquimod cream. Lesions were located on shin, posterior shoulder, and nasal tip. 5% imiquimod cream was applied at night for six weeks. Side effects included erythema and crusting in one patient. Biopsies taken four weeks after treatment revealed no residual squamous cell carcinoma in situ or squamous cell carcinoma. Topical 5% imiquimod cream is becoming established as a promising treatment for squamous cell carcinoma in situ. It also seems to be an alternative treatment for some cases of squamous cell carcinoma.

Original languageEnglish
Pages (from-to)669-673
Number of pages5
JournalJournal of drugs in dermatology : JDD
Volume2
Issue number6
StatePublished - Jan 1 2003

Fingerprint

imiquimod
Bowen's Disease
Squamous Cell Carcinoma
Carcinoma in Situ
Therapeutics
Warts
Basal Cell Carcinoma
Erythema
Nose
Biopsy

Cite this

Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma. / Nouri, Keyvan; O'Connell, Christopher; Rivas, Maria Patricia.

In: Journal of drugs in dermatology : JDD, Vol. 2, No. 6, 01.01.2003, p. 669-673.

Research output: Contribution to journalArticle

Nouri, Keyvan ; O'Connell, Christopher ; Rivas, Maria Patricia. / Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma. In: Journal of drugs in dermatology : JDD. 2003 ; Vol. 2, No. 6. pp. 669-673.
@article{a3807f04e5934b0daa94d828976f4397,
title = "Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma.",
abstract = "Topical imiquimod is an immune response modifier FDA approved for the treatment of anogenital warts. Recent studies have reported its effectiveness in the treatment of some types of basal cell carcinomas. There have also been some case reports and case series reporting success treating of squamous cell carcinoma in situ with imiquimod. We report two patients with squamous cell carcinoma in situ and one with invasive squamous cell carcinoma treated with 5{\%} imiquimod cream. Lesions were located on shin, posterior shoulder, and nasal tip. 5{\%} imiquimod cream was applied at night for six weeks. Side effects included erythema and crusting in one patient. Biopsies taken four weeks after treatment revealed no residual squamous cell carcinoma in situ or squamous cell carcinoma. Topical 5{\%} imiquimod cream is becoming established as a promising treatment for squamous cell carcinoma in situ. It also seems to be an alternative treatment for some cases of squamous cell carcinoma.",
author = "Keyvan Nouri and Christopher O'Connell and Rivas, {Maria Patricia}",
year = "2003",
month = "1",
day = "1",
language = "English",
volume = "2",
pages = "669--673",
journal = "Journal of Drugs in Dermatology",
issn = "1545-9616",
publisher = "Journal of Drugs in Dermatology",
number = "6",

}

TY - JOUR

T1 - Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma.

AU - Nouri, Keyvan

AU - O'Connell, Christopher

AU - Rivas, Maria Patricia

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Topical imiquimod is an immune response modifier FDA approved for the treatment of anogenital warts. Recent studies have reported its effectiveness in the treatment of some types of basal cell carcinomas. There have also been some case reports and case series reporting success treating of squamous cell carcinoma in situ with imiquimod. We report two patients with squamous cell carcinoma in situ and one with invasive squamous cell carcinoma treated with 5% imiquimod cream. Lesions were located on shin, posterior shoulder, and nasal tip. 5% imiquimod cream was applied at night for six weeks. Side effects included erythema and crusting in one patient. Biopsies taken four weeks after treatment revealed no residual squamous cell carcinoma in situ or squamous cell carcinoma. Topical 5% imiquimod cream is becoming established as a promising treatment for squamous cell carcinoma in situ. It also seems to be an alternative treatment for some cases of squamous cell carcinoma.

AB - Topical imiquimod is an immune response modifier FDA approved for the treatment of anogenital warts. Recent studies have reported its effectiveness in the treatment of some types of basal cell carcinomas. There have also been some case reports and case series reporting success treating of squamous cell carcinoma in situ with imiquimod. We report two patients with squamous cell carcinoma in situ and one with invasive squamous cell carcinoma treated with 5% imiquimod cream. Lesions were located on shin, posterior shoulder, and nasal tip. 5% imiquimod cream was applied at night for six weeks. Side effects included erythema and crusting in one patient. Biopsies taken four weeks after treatment revealed no residual squamous cell carcinoma in situ or squamous cell carcinoma. Topical 5% imiquimod cream is becoming established as a promising treatment for squamous cell carcinoma in situ. It also seems to be an alternative treatment for some cases of squamous cell carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=1342266717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1342266717&partnerID=8YFLogxK

M3 - Article

C2 - 14711149

AN - SCOPUS:1342266717

VL - 2

SP - 669

EP - 673

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 6

ER -